These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38238287)

  • 21. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Furuya C; Hashimoto Y; Morishita S; Inano T; Ochiai T; Shirane S; Edahiro Y; Araki M; Ando M; Komatsu N
    Hematology; 2023 Dec; 28(1):2229131. PubMed ID: 37378567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
    Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
    Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
    Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
    Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
    Ben Said M; Gandrille S; Fischer AM; Darnige L
    Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
    Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
    Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
    Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
    Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
    Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
    Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
    Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
    J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
    Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
    Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
    Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
    Barbui T; Falanga A
    Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
    Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
    Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
    Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
    Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
    Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical Analysis of 66 Patients with Essential Thrombocytopenia].
    Zhang LJ; Shi YY; Chen Y; Gan YM; Shi WT; Chen KK; Ding BH; He ZM; Wang CL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1321-1325. PubMed ID: 32798420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.